

10/500216

DT24 Rec'd PCT/PTO 24 JUN 2004

Attorney Docket No.: 61534 (46342)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yuichi Hikichi, et al.
Application No. Not Yet Assigned Art Unit: Not Yet Assigned
Filed: Herewith Examiner: Not Yet Assigned
For: PREVENTIVES/REMEDIES FOR CANCER

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 (Express Mail Label No. EV 438974634 US), and is addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-01450 on June 24, 2004.

By: Kathryn A. Grindrod
Kathryn A. Grindrod

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

10/500216

D Rec'd PCT/PTO 24 JUN 2004

II. COPIES

- a. X Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. X Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. X A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- Please see English Abstract for References BA – BG.
- c. _____ The following additional information is provided for the Examiner's consideration:

FEESIV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)

(check one box)

- a. _____ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. X within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. _____ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):

(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. _____ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

OR

- b. _____ See the certification below. No fee is required.

10/500216

4 Rec'd PCT/PTO 24 JUN 2004

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that


- a. _____ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. _____ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. _____ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

_____ Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

X _____ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,



David G. Conlin (Reg. No. 27,026)
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Tel: (617) 439-4441
Customer No.: 21,874

Date: June 24, 2004

FORM PTO-1449		DOCKET NO: 61534 (46342)		SERIAL NO.: Not Yet Assigned		10/500216	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Y. Hikichi, et al.					
		FILING DATE: Herewith		GROUP NO.: Not Yet Assigned			
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	BA	1 162 274 A1	12/12/2001	EUROPE			Abstract
	BB	WO 96/35784	11/14/1996	PCT			Abstract
	BC	WO 98/31796	07/23/1998	PCT			Abstract
	BD	WO 00/00594	01/06/2000	PCT			Abstract
	BE	WO 01/94620 A1	12/13/2001	PCT			Abstract
	BF	WO 02/090578 A2	11/14/2002	PCT			Abstract
	BG	WO 02/092002 A2	11/21/2002	PCT			Abstract
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	CA	Antoine H.F.M. Peters, et al. <i>Loss Of The Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability</i> , Cell, Vol. 107, pp. 323-337, November 2, 2001					
	CB	S. Czvitkovich, et al. <i>Over-expression Of The SUV39H1 Histone Methyltransferase Induces Altered Proliferation and differentiation In Transgenic Mice</i> , Elsevier Science Ireland Ltd., Vol. 107, pp 141-153, (2001)					
	CC	L. Aagaard, et al. <i>Functional Mammalian Homologues Of The Drosophila PEV-modifier Su(var)3-9 Encode Centromere-Associated Proteins Which Complex With The Heterochromatin Component M31</i> , The EMBO Journal, Vol. 18, No. 7, pp. 1923-1938, (1999)					
	CE	S. J. Nielsen, et al. <i>Rb Targets Histone H3 Methylation and HP1 To Promoters</i> , Nature, Vol. 412, pp. 561-565, August 2, 2001					
	CE	S. Rea, et al. <i>Regulation Of Chromatin Structure By Site-Specific Histone H3 Methyltransferases</i> , Nature, Vol. 406, pp. 593-599, August 10, 2000					
EXAMINER:					DATE:		